Updates are available Correction dated 2022-03-17
Click to view Correction: https://doi.org/10.1245/s10434-022-11599-w
-
Authors
Bagaria, Sanjay P.
Swallow, Carol
Suraweera, Harini
Raut, Chandrajit P.
Fairweather, Mark
Cananzi, Ferdinando
Quagliuolo, Vittorio
Grignani, Giovanni
Hompes, Daphne
Ford, Samuel J.
Nessim, Carolyn
Apte, Sameer
Skoczylas, Jacek
Rutkowski, Piotr
Bonvalot, Sylvie
Tzanis, Dimitri
Gabriel, Emmanuel
Pennacchioli, Elisabetta
Albertsmeier, Markus
Canter, Robert J.
Pollock, Raphael
Grignol, Valerie
Cardona, Kenneth
Gamboa, Adriana C.
Novak, Marko
Stoeckle, Eberhard
Almquist, Martin
Ahuja, Nita
Klemen, Nicholas
Van Houdt, Winan
Gyorki, David
Gangi, Alexandra
Rastrelli, Marco
van der Hage, Jos
Schrage, Yvonne
Valeri, Sergio
Conti, Lorenzo
Spiegel, Matthew R.
Li, Zhou
Fiore, Marco
Gronchi, Alessandro
- License Information
-
More Information
Article History
Received: 27 August 2020
Accepted: 23 January 2021
First Online: 19 March 2021
Change Date: 17 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1245/s10434-022-11599-w
Disclosure
: Giovanni Grignani received grants from PharmaMar, Novartis, and Bayer and was a consultant for Novartis, Bayer, Pharmamar, EISAI, Lilly, and Merck. Piotr Rutkowski received honoraria from MSD, Bristol Myers Squibb, Novartis, Pierre Fabre, Amgen, Sanofi, Merck, Roche, and Blueprint Medicines. Sylvie Bonvalot received honoraria from Nanobiotix and Pharmamar. Nita Ahuja received funding from Astex on developing therapeutics for sarcomas.
